Filtered By:
Condition: Ischemic Stroke
Countries: Switzerland Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 127 results found since Jan 2013.
Cardiac disease prediction using AI algorithms with SelectKBest
AbstractAtherosclerotic cardiovascular disease (ASCVD), which includes coronary heart disease (CHD) and ischemic stroke, is the leading cause of mortality globally. According to the European Society of Cardiology (ESC), 26 million people worldwide have heart disease, with 3.6 million diagnosed each year. Early detection of heart disease will aid in lowering the mortality rate. The lack of diversity in training data and the difficulty in comprehending the findings of complicated AI models are the key issues in current research for heart disease prediction using artificial intelligence. To overcome this, in this paper, cardi...
Source: Medical and Biological Engineering and Computing - September 8, 2023 Category: Biomedical Engineering Source Type: research
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placeboStudy met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi the...
Source: Roche Media News - September 7, 2023 Category: Pharmaceuticals Source Type: news
Ischaemic stroke despite antiplatelet therapy: Causes and outcomes
CONCLUSIONS: One-third of ischaemic strokes occurred despite APT and 20% of patients with a history of ischaemic stroke had no antithrombotic therapy when having stroke recurrence. Aetiology of breakthrough strokes despite APT is heterogeneous and these patients are at increased risk of recurrent stroke.PMID:37622482 | DOI:10.1177/23969873231174942
Source: Atherosclerosis - August 25, 2023 Category: Cardiology Authors: Norbert Silimon Boudewijn Drop Leander Cl énin Krassen Nedeltchev Timo Kahles Alexander A Tarnutzer Mira Katan Leo Bonati Stephan Salmen Sylvan Albert Alexander Salerno Emmanuel Carrera Christian Berger Nils Peters Friedrich Medlin Carlo Cereda Manuel Bo Source Type: research
Association of chocolate consumption with neurological and cardiovascular outcomes in atrial fibrillation: data from two Swiss atrial fibrillation cohort studies (Swiss-AF and BEAT-AF)
CONCLUSION: While chocolate consumption was not associated with MRI findings and major adverse cardiac events in an atrial fibrillation population, No/Low-Ch was associated with a lower cognitive construct score, higher risk of heart failure hospitalisation and increased all-cause mortality compared to Mod-Ch.CLINICALTRIALS: gov Identifier: NCT02105844.PMID:37609948 | DOI:10.57187/smw.2023.40109
Source: Swiss Medical Weekly - August 23, 2023 Category: General Medicine Authors: Annina Stauber Andreas M üller Nikki Rommers Stefanie Aeschbacher Nicolas Rodondi Leo H Bonati Juerg H Beer Raban V Jeger David J Kurz Claudia Liedtke Peter Ammann Marcello Di Valentino Patricia Chocano Richard Kobza Michael K ühne David Conen Stefan Os Source Type: research
Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
Partnership combines Roche ’s proven track record of successfully developing and launching innovative medicines worldwide withAlnylam ’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressureHypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1Basel, 24 July 2023 - Roche (SIX: RO, ROG; OT...
Source: Roche Media News - July 24, 2023 Category: Pharmaceuticals Source Type: news
Positive Phase III results for Roche ’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Phase III OCARINA II trial met primary and secondary endpointsOCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS centres with IV capacity limitations or without IV infrastructureOCREVUS remains the first and only therapy approved for both RMS and PPMS, and more than 300,000 people have been treated globallyBasel, 13 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS ® (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in...
Source: Roche Media News - July 13, 2023 Category: Pharmaceuticals Source Type: news
Mechanism of Gynostemmae Pentaphylli Herba in the treatment of ischemic stroke based on network pharmacology and molecular docking
CONCLUSIONS: Gynostemmae Pentaphylli Herba may play a role in treating ischemic stroke by affecting various pathways through its active ingredients such as Ruvoside_qt, quercetin, 3'-methyleriodictyol, Spinasterol and CLR.PMID:37434834 | PMC:PMC10331645
Source: American Journal of Translational Research - July 12, 2023 Category: Research Authors: Yonglei Liu Jishuai Zhao Jinjiao Song Hongdie Mao Guojing Tan Yaling Zhang Changyun Liu Source Type: research
